#ESMO21 Expert Video Report on NETs
Reporting from the ESMO Congress 2021, Rocio Garcia-Carbonero summarises the interesting results presented in the NETs track including the phase III SPINET study testing lanreotide autogel/depot in patients with advanced lung NETs, response and PFS results from the AXINET study testing axitinib plus octreotide LAR in patients with grade 1-2 extrapancreatic NETs, and the GCO-001 NIPINEC of nivolumab+ipilimumab in pre-treated patients with advanced refractory pulmonary or GEP poorly differentiated NECs, designed to explore the efficacy of immunotherapy in this setting.
Abstracts:
1096O - Lanreotide autogel/depot (LAN) in patients with advanced bronchopulmonary (BP) neuroendocrine tumors (NETs): results from the phase 3 SPINET study - Dr Dieter Horsch, DE
1097O - The AXINET trial (GETNE1107): Axitinib plus octreotide LAR improves PFS by blinded central radiological assessment vs placebo plus octreotide LAR in G1-2 extrapancreatic NETs - Prof Rocio Garcia-Carbonero, ES
LBA41 - Nivolumab (nivo) ± Ipilimumab (ipi) in pre-treated Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) (GCO-001 NIPINEC) - Prof Thomas Walter, FR
The study results covered, and the presenter of this expert video, have been selected exclusively by ESMO.
Produced by the European Society for Medical Oncology
http://oncologypro.esmo.org
Видео #ESMO21 Expert Video Report on NETs канала European Society for Medical Oncology (ESMO)
Abstracts:
1096O - Lanreotide autogel/depot (LAN) in patients with advanced bronchopulmonary (BP) neuroendocrine tumors (NETs): results from the phase 3 SPINET study - Dr Dieter Horsch, DE
1097O - The AXINET trial (GETNE1107): Axitinib plus octreotide LAR improves PFS by blinded central radiological assessment vs placebo plus octreotide LAR in G1-2 extrapancreatic NETs - Prof Rocio Garcia-Carbonero, ES
LBA41 - Nivolumab (nivo) ± Ipilimumab (ipi) in pre-treated Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) (GCO-001 NIPINEC) - Prof Thomas Walter, FR
The study results covered, and the presenter of this expert video, have been selected exclusively by ESMO.
Produced by the European Society for Medical Oncology
http://oncologypro.esmo.org
Видео #ESMO21 Expert Video Report on NETs канала European Society for Medical Oncology (ESMO)
Показать
Комментарии отсутствуют
Информация о видео
12 октября 2021 г. 12:37:03
00:09:17
Другие видео канала
![Expert Report on latest data in the management of metastatic prostate cancer from ASCO 2022](https://i.ytimg.com/vi/IanQNNBfFes/default.jpg)
![OncologyPRO, a 360 research solution designed around you](https://i.ytimg.com/vi/wqzz-57VS70/default.jpg)
![AACR 2023 highlights on advances in the treatment of resected high-risk melanoma with Jeffrey Weber](https://i.ytimg.com/vi/b3b9bg4TSuQ/default.jpg)
![Essentials in bioinformatics and systems biology for oncologists](https://i.ytimg.com/vi/EJjdNVlOtmg/default.jpg)
![ESMO Clinical Unit Visit](https://i.ytimg.com/vi/tXWwr2WQ6XI/default.jpg)
![Supportive care in the context of precision cancer medicine](https://i.ytimg.com/vi/c_XV2lz8V3g/default.jpg)
![Gender Medicine in Oncology - An ESMO Initiative](https://i.ytimg.com/vi/_R77hOzg9io/default.jpg)
![#ESMO21 Highlights on a phase I of dual RAF/MEK inhibitor + FAK inhibitor in ovarian cancer (FRAME)](https://i.ytimg.com/vi/l2I0kIcTaxE/default.jpg)
![Expert Video Report on therapeutic advances in NSCLC from 2021 ASCO Annual Meeting](https://i.ytimg.com/vi/mRhBpXM0mqA/default.jpg)
![ESMO Recommendations for Use of Tumour Multigene NGS in Metastatic Cancers](https://i.ytimg.com/vi/9GL8XvwGySU/default.jpg)
![How Can Cancer Affect Bone Health](https://i.ytimg.com/vi/2x7MURPFGks/default.jpg)
![Personalised medicine: The impact in elderly patients with cancer](https://i.ytimg.com/vi/I4l2nUPUXWA/default.jpg)
![#ESMO23 Head and neck cancer Track highlights with Chair Paolo Bossi](https://i.ytimg.com/vi/Q6IAr7wxO30/default.jpg)
![#ESMO21 Expert Video Report on colorectal cancer](https://i.ytimg.com/vi/zLW6iA1WylM/default.jpg)
![Expert Report on novelties in the management of gynaecological malignancies from ASCO 2022](https://i.ytimg.com/vi/5w4ffWSnltQ/default.jpg)
![#ESMO23 Genitourinary tumours (non-prostate) Track highlights with Chair Michiel van der Heijden](https://i.ytimg.com/vi/8l7tfkgolLo/default.jpg)
![How to select patients with localised soft tissue sarcoma for neoadjuvant/adjuvant chemotherapy?](https://i.ytimg.com/vi/BKBjen9nN2w/default.jpg)
![ESMO OncologyPRO - Intro by Prof. A. MATIKAS](https://i.ytimg.com/vi/vRDxdzlbfek/default.jpg)
![Expert Commentary: Melanoma, Breast and Gynaecological Cancers at ESMO Congress 2021](https://i.ytimg.com/vi/3IqbWbSF4_E/default.jpg)
![Silke Gillessen: Translational research to clinical practice, #ESMO23 to cater for every oncologist](https://i.ytimg.com/vi/mqQYG1m1TRU/default.jpg)
![ESMO 2019 Daily Reporter - Editor's Picks: Ovarian cancer](https://i.ytimg.com/vi/kNi4bEVu8XI/default.jpg)